Document Detail


The brothers RAF.
MedLine Citation:
PMID:  20141832     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Targeted molecular therapies for cancer treatment have shown promise, but also have limitations. In this issue, Heidorn et al. (2010) find that a class of targeted molecular therapies with clinical effectiveness against one melanoma subtype may have adverse clinical effects in another.
Authors:
Lawrence N Kwong; Lynda Chin
Publication Detail:
Type:  Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cell     Volume:  140     ISSN:  1097-4172     ISO Abbreviation:  Cell     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-02-09     Completed Date:  2010-02-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0413066     Medline TA:  Cell     Country:  United States    
Other Details:
Languages:  eng     Pagination:  180-2     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Affiliation:
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / adverse effects
Cell Line, Tumor
Humans
Melanoma / drug therapy*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Proto-Oncogene Proteins c-raf / metabolism
ras Proteins / metabolism
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; EC 2.7.11.1/Proto-Oncogene Proteins B-raf; EC 2.7.11.1/Proto-Oncogene Proteins c-raf; EC 3.6.5.2/ras Proteins
Comments/Corrections
Comment On:
Cell. 2010 Jan 22;140(2):209-21   [PMID:  20141835 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Duct tape for broken chromosomes.
Next Document:  Chaperoning Histones during DNA Replication and Repair.